APA

Azuma J., Ohno M., Kubota R., Yokota S., Nagai T., Tsuyuguchi K., Okuda Y., Takashima T., Kamimura S., Fujio Y. & Kawase I. (20131119). NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy. : European journal of clinical pharmacology.

Chicago

Azuma Junichi, Ohno Masako, Kubota Ryuji, Yokota Soichiro, Nagai Takayuki, Tsuyuguchi Kazunari, Okuda Yasuhisa, Takashima Tetsuya, Kamimura Sayaka, Fujio Yasushi and Kawase Ichiro. 20131119. NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy. : European journal of clinical pharmacology.

Harvard

Azuma J., Ohno M., Kubota R., Yokota S., Nagai T., Tsuyuguchi K., Okuda Y., Takashima T., Kamimura S., Fujio Y. and Kawase I. (20131119). NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy. : European journal of clinical pharmacology.

MLA

Azuma Junichi, Ohno Masako, Kubota Ryuji, Yokota Soichiro, Nagai Takayuki, Tsuyuguchi Kazunari, Okuda Yasuhisa, Takashima Tetsuya, Kamimura Sayaka, Fujio Yasushi and Kawase Ichiro. NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy. : European journal of clinical pharmacology. 20131119.